

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Leu-Fen H. Lin, et al.

Serial No.: 08/182,183

Filed: May 23, 1994

For: Glial Cell Line-Derived Neurotrophic Factor

Docket No.: S-225E

**ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821**

Assistant Commissioner for Patents  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

Respectfully submitted,



Robert L. Sharp  
Attorney/Agent for Applicant(s)  
Registration No.: 45,709  
Phone: (805) 447-5992  
Date: July 10, 2002

Please send all future correspondence to:

U.S. Patent Operations/RLS  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**\*Express Mail® mail labeling number: EL360687369USDate of Deposit: July 10, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

S.L. ST. ANDREW  
Printed Name

S.L. St. Andrew  
Signature